Table II.
The top 5 enriched down- and upmethylated pathways involved in the development of lung adenocarcinoma.
| Cluster | ID | P-value | P-adjust | Count |
|---|---|---|---|---|
| Downmethylated | GO:0005244 | 2.52E-12 | 1.13E-09 | 52 |
| Downmethylated | GO:0022832 | 2.52E-12 | 1.13E-09 | 52 |
| Downmethylated | GO:0005261 | 8.86E-12 | 2.66E-09 | 69 |
| Downmethylated | GO:0022843 | 5.10E-11 | 1.15E-08 | 40 |
| Downmethylated | GO:0004984 | 2.64E-10 | 4.00E-08 | 84 |
| Upmethylated | GO:0000982 | 4.19E-22 | 4.13E-19 | 124 |
| Upmethylated | GO:0001228 | 3.7E-20 | 1.82E-17 | 116 |
| Upmethylated | GO:0001077 | 1.35E-15 | 4.43E-13 | 85 |
| Upmethylated | GO:0001159 | 1.92E-13 | 4.74E-11 | 113 |
| Upmethylated | GO:0000987 | 1.55E-12 | 3.05E-10 | 110 |
GO, Gene Ontology.